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What health professionals should know about  
omega-3 fatty acid supplements
Introduction 
Omega-3 (n-3) polyunsaturated fatty acids are a congregate of fatty 
acids that are essential in maintaining satisfactory human health. 
a-linolenic acid (ALA) is a plant-derived n-3 fatty acid, and serves 
as the parent fatty acid of the n-3 series. However, ALA cannot be 
produced in the human body and needs to be consumed in the diet. 
Through a series of steps, ALA is metabolised into eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA). Food sources of ALA 
include flaxseed (linseed) and the oils of walnut, rapeseed (canola) 
and soya. However, the conversion rates of plant-derived ALA to 
EPA are approximately 8-20% in humans, but the conversion from 
ALA to DHA is only 0.5-9%.1 In contrast to plant-derived n-3 fatty 
acids, marine n-3 fatty acids contain preformed EPA and DHA 
which can be consumed directly from cold water oily fish, such as 
sardines, anchovies, Chinook salmon, Atlantic salmon, herring, trout 
and oysters.2 The importance of marine-derived EPA and DHA has 
been comprehensively studied, but the role of the plant-derived 
counterpart ALA is uncertain, despite the fact that ALA is the principal 
n-3 fatty acid in the Western diet.1 In general, EPA interferes with 
the arachidonic acid cascade,3 demonstrating anti-inflammatory 
and anti-aggregatory characteristics, while DHA is essential for 
neurological development. 
Marine-derived n-3 fatty acids have been linked to a number of 
beneficial effects in various disease and inflammatory related 
conditions. The role of chronic low-grade inflammation in the 
development and progression of chronic diseases,4 including 
cardiovascular disease, type 2 diabetes, cancer, rheumatoid arthritis 
and Alzheimer’s disease5 is becoming increasingly important. The 
potent anti-inflammatory properties of n-3 fatty acids have been 
shown to play a preventative role in the development of these 
conditions. Other conditions with inflammatory components in which 
n-3 fatty acids might be of benefit include obesity, Crohn’s disease, 
ulcerative colitis, type 1 diabetes, asthma, psoriasis, multiple 
sclerosis, cystic fibrosis and chronic obstructive pulmonary disease.3 
The protective effects of n-3 fatty acids against coronary heart 
disease6 and their significance in neural and visual development7 
are well documented. Researchers are becoming more interested 
in the role of n-3 fatty acids in the prevention and treatment of 
psychiatric-related conditions, such as depression and attention 
deficit hyperactivity disorder.8  
As it is not always possible to consume adequate amounts of n-3 
fatty acids through the diet, interest in n-3 fatty acid supplements 
has soared. Certain groups of people are prone to n-3 fatty acid 
deficiencies so supplementation might be an option through which 
to increase their n-3 intake. Such risk groups include the geriatric 
population, pregnant women, individuals with compromised 
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nutritional status, and those with a limited variety in food selection 
which prevents them from achieving nutrient adequacy. However, 
information pertaining to dietary intake recommendations, the 
bioavailability of n-3 fatty acid supplements, labelling information 
and potential adverse effects is limited, and health professionals 
may not be able to advise consumers with sufficient information. 
These aspects are addressed.   
Dietary intake recommendations 
Dietary recommendations and advice for the intake of n-3 fatty acids 
have progressed notably over the past five years. However, no formal 
dietary reference intakes currently exist for EPA and DHA. Because 
of the wide range of reputed health benefits associated with EPA 
and DHA, a number of international organisations and agencies have 
proposed recommendations for EPA and DHA, as well as daily fish 
intake for health promotion and disease prevention. A summary of 
international recommendations on the dietary intake of fish and fish 
oil is listed in Table I.  
Table I: Recommendations for omega-3 fatty acid intake in adults 
according to different bodies
Group Recommendation
American Heart Association9 Primary CHD prevention: 500 mg/
day EPA plus DHA or two portions 
fatty fish/week
Secondary CHD prevention: 1 g/day 
EPA plus DHA
American Dietetic Association and 
Dietitians of Canada10
500 mg/day EPA plus DHA 
Eurodiet11 200 mg/day EPA plus DHA
Fourth Joint Task Force of the 
European Society of Cardiology12
Two portions fatty fish/week
Secondary CHD prevention: 1 g/day 
EPA plus DHA
United Kingdom Scientific Advisory 
Committee on Nutrition6
At least two servings/week, of 
which one should be oily and 
provide 450 mg/day EPA plus DHA
International  Society  for the  Study 
of Fatty Acids and Lipids13
500 mg/day EPA plus DHA
Perinatal Lipid Intake Working 
Group14
At least 200 mg/day DHA during 
pregnancy and lactation 
World Association of Perinatal 
Medicine, Early Nutrition Academy 
and Child Health Foundation 
(Pregnancy and Lactation)15
200-300 mg/day DHA
CHD: coronary heart disease, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid
The ideal is that these dietary intake recommendations for n-3 fatty 
acids should be achieved by consuming oily fish, as well as plant-
derived n-3 fatty acid sources on a regular basis. For the consumer, 
meeting these dietary recommendations might be difficult to achieve, 
especially in vulnerable population groups, where a supplement 
might be helpful to increase their dietary intake of n-3 fatty acids. 
In order to reach a recommended intake of 500 mg/day13 to 600 
mg/day16 EPA and DHA intake by using supplements, an intake of 
approximately 2 000 mg fish oil with a 180 mg EPA:120 mg DHA 
content ratio17 would be required. To consume these amounts of 
EPA plus DHA through diet or non-supplementation, approximately 
50 g/day of bluefin tuna, or 60 g/day of pilchards, or 52 g/day of 
salmon2 should be consumed. These amounts will vary according 
to the geographic origin and harvest season of the fish. In addition, 
the preparation method of the fish prior to consumption influences 
levels of EPA and DHA. Regular consumption of quality supplements 
would be a more convenient method of supplying n-3 fatty acids in 
adequate amounts to consumers.
Bioavailability of omega-3 fish oil supplements
The bioavailability of dietary supplements refers to the proportion of 
a substance that the human gastrointestinal tract is able to absorb 
and assemble for use or storage.18 In nature, virtually all fats and oils 
comprise triglycerides (TGs). The n-3 fatty acids present in fish are 
almost exclusively TGs. However, not all n-3 fatty acid formulations 
on the South African market are encapsulated as TGs, but may 
be processed to ethyl esters (EEs) or re-esterified TGs (rTGs)19 by 
manufacturers.  
Structure of the fatty acid
The bioavailability of EPA and DHA in TG, EE or rTG forms varies, and 
may be a concern for the South African consumer as South African 
fish oil supplement labels do not specify the form of n-3 fatty acids 
present. In the USA, the majority of n-3 fatty acid preparations are 
available as either EEs or rTGs.20 The EEs are the esterified products 
of fatty acids and ethanol. This chemical process is known as trans-
esterification and involves the removal of the glycerol backbone 
of the TGs by substituting them with ethanol. By using fractional 
distillation, which removes short-chain and saturated fatty acids, it 
is now possible for manufacturers of these supplements to allow for 
selective concentration of EPA and DHA to levels in excess of those 
found in natural fish oils. Esterification is also applied to deodorise 
the fish oil. These preparations are typically marketed as fish oil 
concentrates. Through the process of glycerolysis, it is possible to 
convert EEs back to TGs. This process removes the ethanol molecule 
and re-esterifies the EPA and DHA fatty acids back to a glycerol 
backbone, resulting in the formation of rTGs.21 
Because of the absence of a glycerol backbone of EEs, their digestion 
is altered. Pancreatic lipase is the enzyme that hydrolyses the fatty 
acids from the ethanol backbone in the small intestine. However, the 
fatty acid ethanol bond of EEs is much more resistant to hydrolysis 
by pancreatic lipase, when compared to the hydrolysis of TGs in the 
natural form, and may reduce the bioavailability of EEs. Consequently, 
the digestion and absorption of EEs is significantly lower compared 
to TGs and phospholipids (PLs). EEs are also thought to be highly 
dependent on the fat content of a meal. Higher fat meals would 
stimulate pancreatic enzyme activity overall, and thereby enhance 
absorption.22
More recently, Dyerberg et al20 conducted a two-week clinical trial 
on 72 healthy individuals divided into six groups. N-3 fatty acid 
preparations containing 3.3 g EPA and DHA per day in EE, free fatty 
acid, or rTG form, were administered to three of the groups. The 
remaining three groups received cod liver oil, or fish body oil or a 
placebo.  Increases in the absolute values of EPA and DHA were 
measured in fasting-serum TGs, cholesterol esters and PLs. The 
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rTGs demonstrated maximum bioavailability (124%) of EPA and 
DHA, when compared to the group consuming natural fish oil, while 
the bioavailability of EE was less (73%). No significant difference 
between the bioavailability of free fatty acids (91%) and natural TGs 
was observed.  
In another randomised clinical trial over a six-month period, 150 
healthy individuals received moderate doses of EPA and DHA (1 680 
mg/day), administered either as rTGs or as EEs. A placebo group 
receiving corn oil was also included. The n-3 index (EPA plus DHA 
in red blood cell membranes, expressed as a percentage of total 
fatty acids) was determined at baseline, after three, and six, months 
of treatment. After three months, it was reported that rTG levels 
resulted in a significantly increased n-3 index (186% increase from 
the baseline). In addition, this resulted in a more rapid incorporation 
of EPA and DHA into the red blood cell membrane fatty acids (a 160% 
increase from baseline) when compared to the EEs.23After six months, 
the increases in the n-3 index from baseline were significantly 
higher for rTGs (197%) compared to EEs (171%). This observation 
indicated more rapid and maximum increases in the n-3 index 
derived from rTGs, when compared to EEs.22 In a subset of subjects 
from this study (150 dyslipidaemic statin-treated participants) who 
also received either rTG, EE or corn oil capsules, the n-3 index was 
significantly higher in the rTG group, when compared to the placebo 
and the EE group after both three and six months. No significant 
difference was reported for blood TG levels between the rTG and EE 
groups after both time intervals.19
Krill oil
Krill oil (KO) is a relatively new source of n-3 fatty acids. The 
bioavailability of KO is reportedly increased because of the 
esterification of n-3 fatty acids in PLs, rather than from TGs or EEs.24 
However, findings of recent clinical trials concerning the increased 
bioavailability of EPA and DHA from KO were not conclusive when 
compared to studies involving EPA and DHA bound to TGs. Maki et al25 
performed a randomised, double-blind clinical trial on 76 obese men 
and women over a four-week period. Participants received capsules 
with 2 000 mg/day KO (216 mg EPA and 90 mg DHA), menhaden oil 
(212 mg EPA and 178 mg DHA), or olive oil. No significant differences 
in the absorption of plasma EPA and DHA between the krill and 
menhaden oil groups were reported. Ulven et al26 reported similar 
non-significant changes between plasma EPA and DHA for fish oil 
(864 mg total n-3 fatty acids) and KO (543 mg total n-3 fatty acids) in 
a randomised, parallel group clinical trial of seven weeks’ duration. 
They compared the uptake of EPA and DHA between fish oil and 
KO in 113 healthy participants. It was concluded that both KO and 
fish oil represented comparable dietary sources of n-3 fatty acids. 
Schuchardt et al19 administered 1 680 mg EPA and DHA in the form of 
rTGs, EEs or KO to 12 healthy young men. The fatty acid levels were 
analysed in plasma PLs prior to supplementation 2, 4, 6, 8, 24, 48 
and 72 hours after supplementation. In general, the incorporation of 
EPA and DHA in plasma PLs was maximal with KO supplementation, 
followed by rTGs and EEs. Unfortunately, this study did not include 
fish oil in the TG form to be compared to rTGs and EEs.  
Frequency of fish oil intake
Current research conducted by our group suggests that n-3 fatty 
acids need to be ingested continuously, preferably on a daily basis. 
In a randomised, controlled trial on healthy adults, 1 200 mg/
day salmon oil was administered over a six-week loading period. 
It was observed that the disappearance rates of EPA from TGs, 
cholesterol esters and total PLs were dissimilar on termination 
of the loading period. With cessation of the loading period, 50% 
of the participants discontinued supplementation and a washout 
period of six weeks was implemented. The EPA demonstrated the 
most rapid disappearance rate from TG (half life (t½) = 3 days) and 
total PLs (t½ = 5.5 days) was the longest.  After 21 days without 
supplementation, EPA levels in the TGs returned to baseline levels.16 
In red blood cells (RBCs), the disappearance rates of EPA from the 
phosphatidyl choline (PC) membranes were shortest (t½ = 5.5 days) 
when compared to the phosphatidyl ethanolamine membranes (t½ = 
> 7 days). The EPA levels in the PC membranes returned to baseline 
levels after 21 days.27 Instead of following the washout period, the 
remaining 50% of the participants continued with 600 mg/day 
salmon oil. During the following six weeks, the n-3 fatty acid levels 
of these participants stabilised and were maintained at levels above 
the baseline. Measured dietary fat intake remained constant over 
the course of the trial. Considering the rapid disappearance rates of 
n-3 fatty acids from plasma lipids and RBCs, it is recommended that 
n-3 fatty acids should be taken on a regular basis to ensure that n-3 
levels are maintained above baseline values in the blood.
It should be kept in mind that dietary fat is mainly ingested in the 
form of TGs. The TGs cannot be readily absorbed in the intestine. 
Instead, to ensure absorption, TGs must be converted to free fatty 
acids and monoglycerides in the presence of pancreatic lipase. In 
pure fish oil, EPA and DHA are bound to TGs and therefore also utilise 
lipases for absorption. For this reason, it is recommended that fish 
oil supplements should be consumed in combination with a fat-
containing meal.  
Labelling legislation
South African consumers have grown accustomed to the quality 
inherent in the manufacture of conventional medicinal products as 
stipulated by the Medicines Control Council. Usually, they accept the 
consistency, purity and potency of prescription and non-prescription 
medications and preparations without question. Consequently, 
consumers have little reason to doubt the package label claims 
on conventional medication. However, a similar claim cannot be 
made for dietary supplements since no regulatory structure for 
dietary supplements currently exists. The Foodstuff Cosmetics and 
Disinfectants Act No 54 of 1972 (Amendment No 39 of 2007)28 does 
not supply any definitions for dietary or nutritional supplements, nor 
does the new Labelling and Advertising of Foodstuffs Regulations 
(R146),29 published in 2010. Instead, dietary supplements are 
included in the wider-ranging definition of foodstuffs. While this 
definition is comprehensive for the description of a foodstuff, it 
does not explain explicit differences between foodstuffs and dietary 
supplements. Consequently, the requirements and procedures for 
the quality control, packaging, labelling and presentation of both 
dietary supplements and foodstuffs are identical.  
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Quality control needs to be addressed during the manufacturing, 
production and commercialisation of n-3 fatty acid supplements, 
as these should not be the same as that for foodstuffs containing 
n-3 fatty acids. In a recent first analysis in South Africa on the 
n-3 fatty acid content of 45 fish oil supplements available on the 
South African market, concerns were raised about the quality of 
these supplements. Analysis of the n-3 fatty acid content of fish 
oil supplements indicated that 51% and 56% of the EPA and DHA 
contents, respectively, were at levels lower than the levels reported 
on the supplement labels. In addition, the conjugated diene (CD) 
levels of the supplement oils were determined. The CD levels are an 
indication of early stages of rancidity. Elevated CD levels implicate 
deterioration in the quality of oils. The comparison of the CD contents 
of the supplement oils to those of unopened canola, sunflower and 
olive oil, revealed that more than 73% of the oils in the supplements 
displayed higher CD levels than the vegetable oils.30 
N-3 fatty acids, in the form of supplements, appear to be the safer 
and more controllable way of consuming n-3 fatty acids. However, all 
preparations rely on fish oil as a source of EPA and DHA. Importantly, 
the n-3 fatty acid content of deep-sea oily fish, from which fish oil 
preparations are derived, is influenced by the geographic origin of 
the fish, as well as the season of harvest. Thus, the fatty acid content 
in fish varies significantly. Poor quality of raw materials, suboptimal 
storage conditions, as well as inconsistency in the potency and 
purity of fish oil, further contribute to the variability of the fatty acid 
content in fish oil supplements. As inconsistent fatty acid content 
in supplements may contribute to errors in daily dosage and 
associated unfavourable dose-related side effects, proper legislation 
is essential to ensure consistency in the n-3 fatty acid content of 
fish oil-derived supplements. Accurate information on supplement 
labels will empower the consumer to make an informed decision 
about the number of capsules that supply a certain dose of EPA 
and DHA, as well as aid them in choosing a supplement that will 
suit their lifestyle. Potential solutions would be to perform batch-
by-batch analyses, accompanied by the provision of a certificate of 
analysis, on the n-3 fatty acid content of supplements. Ideally, these 
recommendations should be mandatory and enforced by appropriate 
legislation regarding the manufacture of all dietary supplements. 
Because of the lack of appropriate legislation, many claims made 
by manufacturers of dietary supplements remain unchallenged. 
Companies that manufacture or distribute fish oil or fish oil 
combination supplements need to ensure the safety of these 
supplements by authenticating any representations or claims made 
on the product by means of relevant and evidence-based research. 
This would prevent claims that are both false and misleading. This 
evidence should be accessible to consumers. Consumers should 
also be made aware that even when implementing current good 
manufacturing practice guidelines during the production process, 
the safety of the product is not guaranteed.  Separate regulations 
on purity, bioavailability, potency, possible adverse effects, safety 
aspects, active ingredients, allergies and contraindications of 
supplements should also be stipulated. A legislative body to address 
these issues should be created to ensure enforcement of the 
legislation.  
Potential adverse effects
Although evidence-based research has confirmed that increased 
intakes of n-3 fatty acids are valuable for some health conditions, 
n-3 supplements should to be used with caution. Excess intakes 
of n-3 fatty acids in healthy populations may lead to undesirable 
side-effects, such as the suppression of the immune system, nose 
bleeds in individuals with hypercholesterolaemia, and prolonged 
bleeding time with increased risk of haemorrhagic strokes and 
increased levels of lipid peroxidation.2 In addition, the simultaneous 
intake of n-3 fatty acids with anticoagulant medication, such as 
aspirin and warfarin, prolongs bleeding times in individuals using 
these medications. Currently, no supporting data exist to establish a 
safe upper limit for n-3 fatty acids. However, the US Food and Drug 
Administration has ruled that intakes of up to 3 g/day of marine n-3 
fatty acids are “generally recognised as safe” for inclusion in the 
diet.31
A further concern is the effect of fish oil supplementation on 
lipoprotein cholesterol levels. Recent meta-analyses and systematic 
reviews32 have reported that treatment with EPA or DHA showed 
diverse effects on high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) cholesterol. Both treatments induced lower blood 
TG levels. However, DHA was more often associated with both 
elevated HDL cholesterol levels and increased LDL cholesterol levels. 
The increase in LDL cholesterol is undesirable. However, clinical 
trials elsewhere33,34 have indicated that fish oil supplementation is 
associated with increased LDL cholesterol particle size, or a shift in 
LDL cholesterol particle distribution from small, dense particles to 
larger, less dense LDL cholesterol particles which are known to be 
less atherogenic.   
General advice
Consumers are often confused as to which n-3 supplements to 
purchase. Since it has been reported that there is a limited conversion 
of plant-derived n-3 fatty acids to EPA and DHA, consumers are 
advised to purchase pure fish oil supplements, in which other 
additional fatty acids are absent. Many fish oil supplements are 
often combined with n-6 and n-9 fatty acids. As these two latter fatty 
acids are abundant in the Western diet, they should not be further 
supplemented. Current general recommended daily intakes of n-3 
fatty acids are approximately 500 mg/day.  Therefore, consumers 
should be advised to purchase supplements that contain these 
amounts. Excess fish oil consumption (> 3 000 mg/day) should be 
avoided. Supplement labels should clearly indicate the exact contents 
of both the fish oil supplement and the EPA and DHA contents in 
a capsule. Furthermore, the source of fish oil should be indicated. 
Health professionals could advise consumers to buy supplements 
from an outlet where they have not been stored on shelves for 
excessive periods of time where light exposure is a problem. Hence, 
consumers should avoid buying supplements that are packaged in 
clear containers since exposure to light may enhance the rancidity of 
the oils. Consumers are also advised not to use supplements beyond 
the expiry date. It is also not always the rule that the most expensive 
supplements represent optimum quality.
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As indicated in the foregoing, fish oil supplements are not 
safeguarded against false and misleading claims. Consumers should 
scrutinise rare claims that are made on supplement labels. If claims 
sound too good to be true, they usually are! To promote a product, 
many supplement manufacturers make unsubstantiated claims on 
labels and increase product sales. This also undoubtedly benefits 
company research, development and competitiveness. Forged, 
misleading claims create idealistic expectations and waste money. 
Such unethical practices can cause an incorrect supplement dosage, 
thus leading to detrimental health effects. Several companies base 
their evidence on animal data which cannot be extrapolated to the 
human system. Supplement users should always vigilantly compare 
health claims with evidence-based research, or properly consult 
trained nutrition professionals. Consumers who are allergic to fish 
should avoid taking fish oil supplements. Preferably, supplements 
should be purchased from reputable companies that provide a 
certificate of analysis with proven quality control. 
Finally, pregnant and lactating women must familiarise themselves 
with the contents of any n-3 supplement.  Supplements are often sold 
as a combination of fish oil, amended with vitamins and/or minerals. 
Therefore, additional supplementation of the specific vitamin and/
or mineral should be avoided to prevent overconsumption during 
pregnancy. A further concern is the EE content in n-3 fatty acid 
supplements. In a recent survey conducted by our group, it was 
discovered that a third of n-3 fatty acid supplements available on the 
South African market consist of EEs. Pregnant women are advised 
against the use of EEs since the safety of EEs during pregnancy has 
not been established. When EEs are converted back to TGs during 
digestion, alcohol is released. Even though the quantity of ethanol 
released in a typical dose of fish oil via supplementation is small, at-
risk groups such as alcoholics, pregnant women and young children 
should refrain from using n-3 fatty acid supplements that contain 
EEs. The EEs of fatty acids has shown toxicity in vivo35 and in vitro,36 
and is known to accumulate in major organs, such as the heart, 
liver, pancreas, and potentially the placenta.37 In a rat study,38 it was 
observed that efficient fatty acid EE digestion in the gastrointestinal 
tract may prevent toxicity. However, this was not confirmed in 
humans. At present, no manufacturers indicate the form (EEs, TGs 
and or rTGs) in which n-3 fatty acids are present in capsules.  
Conclusion
Following a typical Western diet complicates the optimal dietary intake 
of EPA and DHA. Generally, it is believed that fish oil supplements 
are a safe and easy method of accomplishing favourable n-3 fatty 
acid intakes. However, several factors need to be considered when 
choosing a fish oil supplement. The bioavailability of EPA and DHA in 
TG, EE or rTG forms varies, and may be a concern as South African 
fish oil supplement labels do not specify the form of n-3 fatty acids 
present. From the literature, it appears that EPA and DHA, in the form 
of TGs, rTGs and PLs, are absorbed more efficiently, compared to 
the EE form. During digestion, EEs are converted back to TGs, while 
ethanol is released. The safety of fish oil supplements in the form 
of EEs has not been confirmed. Vulnerable groups, like alcoholics, 
pregnant women and young children, should refrain from taking 
EEs. It is recommended that fish oil supplements should be taken 
every 24-48 hours to ensure that n-3 blood levels are maintained 
above baseline. Taking n-3 fatty acid supplements in combination 
with a fat-containing meal may aid in improving absorption. Recent 
reviews reported the diverse effects of EPA and DHA on lipoprotein 
cholesterol. DHA was more often associated with an increase in 
LDL cholesterol and HDL cholesterol. Fish oil supplementation 
was associated with less dense, larger LDL cholesterol and HDL 
cholesterol particles which are cardioprotective.  
Finally, the absence of a regulatory structure for dietary supplements 
is a major concern for South Africans. Such a regulatory structure 
is fundamental in protecting consumers against substandard 
supplements and false, misleading claims that might adversely affect 
their health. Therefore, South African health professionals should 
assist patients by obliging government to establish appropriate and 
mandatory legislation for all dietary supplements. 
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